Taking it personally, cutting-edge biotech snags $45 million
As Dr. Hal Dietz fielded offers to spin out his research from Johns Hopkins University into a venture-backed biotech company focused on fibrotic diseases, he turned to MPM Capital's Luke Evnin.
Evnin, a founder of MPM, is chairman of the Scleroderma Research Foundation, which had funded Dietz's fibrosis research work over the last seven or eight years with $1 million. It is a role that has given Evnin a front-row seat to the work done in academic labs aimed at skin-thickening and connective tissue…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Academia | Biotechnology | Health | Health Management | John Hopkins University | Nutrition | Scleroderma | Skin